Dr. Reddy's Laboratories Limited (RDY)
NYSE: RDY · Real-Time Price · USD
14.24
+0.03 (0.21%)
At close: Aug 27, 2025, 4:00 PM
14.24
0.00 (0.00%)
After-hours: Aug 27, 2025, 7:00 PM EDT
Dr. Reddy's Laboratories Employees
Dr. Reddy's Laboratories had 27,811 employees as of March 31, 2025. The number of employees increased by 763 or 2.82% compared to the previous year.
Employees
27,811
Change (1Y)
763
Growth (1Y)
2.82%
Revenue / Employee
$140,139
Profits / Employee
$23,814
Market Cap
12.00B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 27,811 | 763 | 2.82% |
Mar 31, 2024 | 27,048 | 1,185 | 4.58% |
Mar 31, 2023 | 25,863 | 1,068 | 4.31% |
Mar 31, 2022 | 24,795 | 2,056 | 9.04% |
Mar 31, 2021 | 22,739 | 1,089 | 5.03% |
Mar 31, 2020 | 21,650 | -316 | -1.44% |
Mar 31, 2019 | 21,966 | -1,558 | -6.62% |
Mar 31, 2018 | 23,524 | 853 | 3.76% |
Mar 31, 2017 | 22,671 | 496 | 2.24% |
Mar 31, 2016 | 22,175 | 1,802 | 8.85% |
Mar 31, 2015 | 20,373 | 1,952 | 10.60% |
Mar 31, 2014 | 18,421 | 1,804 | 10.86% |
Mar 31, 2013 | 16,617 | 1,417 | 9.32% |
Mar 31, 2012 | 15,200 | 277 | 1.86% |
Mar 31, 2011 | 14,923 | 1,468 | 10.91% |
Mar 31, 2010 | 13,455 | 2,227 | 19.83% |
Mar 31, 2009 | 11,228 | 1,653 | 17.26% |
Mar 31, 2008 | 9,575 | 555 | 6.15% |
Mar 31, 2007 | 9,020 | 1,495 | 19.87% |
Mar 31, 2006 | 7,525 | 1,390 | 22.66% |
Mar 31, 2005 | 6,135 | -20 | -0.32% |
Mar 31, 2004 | 6,155 | 303 | 5.18% |
Mar 31, 2003 | 5,852 | 409 | 7.51% |
Mar 31, 2002 | 5,443 | 314 | 6.12% |
Mar 31, 2001 | 5,129 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
RDY News
- 9 days ago - Extrovis AG and Dr. Reddy's announce the launch of the authorized generic of CARAC (fluorouracil cream), 0.5% in the U.S. - GlobeNewsWire
- 5 weeks ago - Dr. Reddy's Laboratories Limited (RDY) Q1 2026 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Dr. Reddy's Q1FY26 Financial Results - Business Wire
- 5 weeks ago - India's Dr Reddy's to launch generic obesity drugs in 87 countries next year, CEO says - Reuters
- 2 months ago - Dr Reddy's And Alvotech Join Hands To Develop Biosimilar For Merck's Blockbuster Cancer Drug - Benzinga
- 2 months ago - Alvotech and Dr. Reddy's Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab) - Business Wire
- 3 months ago - Dr. Reddy's Continues To Be A Good Buy At Current Valuation - Seeking Alpha
- 3 months ago - Dr. Reddy's Laboratories Limited (RDY) Q4 2025 Earnings Call Transcript - Seeking Alpha